These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26636658)

  • 21. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
    Honma Y; Nagashima K; Hirano H; Shoji H; Iwasa S; Takashima A; Okita N; Kato K; Boku N; Murakami N; Inaba K; Ito Y; Itami J; Kanamori J; Oguma J; Daiko H
    Cancer Med; 2020 Jan; 9(2):595-604. PubMed ID: 31794158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
    Okuma HS; Iwasa S; Shoji H; Takashima A; Okita N; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y
    Anticancer Res; 2014 Sep; 34(9):5037-41. PubMed ID: 25202088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
    Li DX; Chen XB
    Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).
    Lamarca A; Frizziero M; Barriuso J; McNamara MG; Hubner RA; Valle JW
    Clin Transl Oncol; 2019 Jul; 21(7):950-953. PubMed ID: 30506132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.
    Lee YC; McCrystal MR; Christmas TI
    N Z Med J; 1998 Nov; 111(1078):451-2, 453-4. PubMed ID: 9891564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
    Lee HS; Lee YG; Koo DH; Oh S; Nam H; Song JU; Lim SY; Lim SY; Lee SS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):933-7. PubMed ID: 26374553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
    Gupta A; Duque M; Saif MW
    JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
    Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
    Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
    van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
    Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
    Welin S; Sorbye H; Sebjornsen S; Knappskog S; Busch C; Oberg K
    Cancer; 2011 Oct; 117(20):4617-22. PubMed ID: 21456005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy.
    Zivanovic O; Leitao MM; Park KJ; Zhao H; Diaz JP; Konner J; Alektiar K; Chi DS; Abu-Rustum NR; Aghajanian C
    Gynecol Oncol; 2009 Mar; 112(3):590-3. PubMed ID: 19110302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
    Yoshimura A; Noro R; Miyanaga A; Mizutani H; Kosaihira S; Minegishi Y; Seike M; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Gemma A;
    Anticancer Res; 2012 Oct; 32(10):4473-8. PubMed ID: 23060575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin.
    Yilmaz U; Polat G; Anar C; Halilcolar H
    Indian J Cancer; 2011; 48(4):454-9. PubMed ID: 22293260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
    Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
    Morizane C; Machida N; Honma Y; Okusaka T; Boku N; Kato K; Nomura S; Hiraoka N; Sekine S; Taniguchi H; Okano N; Yamaguchi K; Sato T; Ikeda M; Mizuno N; Ozaka M; Kataoka T; Ueno M; Kitagawa Y; Terashima M; Furuse J;
    JAMA Oncol; 2022 Oct; 8(10):1447-1455. PubMed ID: 35980649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
    Charpidou A; Tsagouli S; Tsimpoukis S; Vassias A; Makrilia N; Stratakos G; Gkiozos I; Syrigos K
    Anticancer Drugs; 2010 Jul; 21(6):651-5. PubMed ID: 20386306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
    Hainsworth JD; Stroup SL; Greco FA
    Cancer; 1996 Jun; 77(12):2458-63. PubMed ID: 8640693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer: a systemic analysis of case series.
    Gao R; Zhang Y; Wen XP; Fu J; Zhang GJ
    Dis Esophagus; 2014; 27(8):764-9. PubMed ID: 24118373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.